Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: Double-blind placebo-controlled trial

Neurogastroenterology and Motility

Volumn 26, Issue 5, 2014, Pages 670-678

  Ostovaneh, M R ^a,b   Saeidi, B ^b   Hajifathalian, K ^c   Farrokhi Khajeh Pasha, Y ^b   Fotouhi, A ^b   Mirbagheri, S S ^b   Emami, H ^b   Barzin, G ^b   Mirbagheri, S A ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antidepressive agents; Gastro esophageal reflux; Heartburn; Proton pump inhibitors; Serotonin uptake inhibitors

Indexed keywords

FLUOXETINE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEARTBURN; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; TREATMENT OUTCOME;

ADULT; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HEARTBURN; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; RETREATMENT; TREATMENT OUTCOME;

EID: 84898826700     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12313     Document Type: Article

References (31)

1. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58: 295-309.
2. Crawley J, Schmitt C. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. JCOM 2000; 7: 29-34.
3. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007; 41: 131-7.
4. Dean B, Gano A Jr, Knight K, Ofman J, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux. Clin Gastroenterol Hepatol 2004; 2: 656-64.
5. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10: 119-24.
6. Tack J, Fass R. Approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther 2004; 19 (Suppl.): 28-34.
7. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002; 51: 885-92.
8. Wu JCY, Cheung CMY, Wong VWS, Sung JJY. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5: 690-5.
9. Nojkov B, Rubenstein J, Adlis S, Shaw M, Saad R, Rai J, Weinman B, Chey WD et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27: 473-82.
10. America H. A Gallup Organization National Survey. Princeton, NJ: Gallup Organization, 1988.
11. Devault KR. The role of acid suppression in patients with non-erosive reflux disease or functional heartburn. Aliment Pharmacol Ther 2006; 23 (Suppl.): 33-9.
12. Cannon R, Quyyumi A, Mincemoyer R, Stine A, Gracely R, Smith W, Geraci MF, Black BC et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994; 330: 1411-7.
13. Varia I, Logue E, O'Connor C, Newby K, Wagner HR, Davenport C, Rathey K, Krishnan KR et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 2000; 140: 367-72.
14. Savarino E, Pohl D, Zentilin P, Dulbecco P, Sammito G, Sconfienza L, Vigneri S, Camerini G et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009; 58: 1185-91.
15. Fass R, Chey W, Zakko S, Andhivarothai N, Palmer R, Perez M, Atkinson SN. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2009; 29: 1261-72.
16. Rentz A, Kahrilas P, Stanghellini V, Tack J, Talley N, De la loge C, Tradeau E, Dubois D et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res 2004; 13: 1737-49.
17. Heidelbaugh J, Goldberg K, Inadomi J. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk in PPI. Am J Gastroenterol 2009; 104: S27-32.
18. Pham C, Sadowski-Hayes L, Regal R. Prevalent prescribing of proton pump inhibitors: prudent or pernicious? P AND T 2006; 31: 159-67.
19. Force RW, Meeker AD, Cady PS, Culbertson VL, Force WS, Kelley CM. Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003; 37: 490-3.
20. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-95.
21. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53.
22. Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil 2012; 24: 747-57.
23. Pace F, Santalucia F, Porro GB. Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut 1991; 32: 845-8.
24. Carlsson R, Frison L, Lundell L, Dent J. Relationship between symptoms, endoscopic findings and treatment outcome in reflux esophagitis. Gastroenterology 1996; 110: A77.
25. Bradley L, Richter J, Pulliam T, Haile J, Scarinci I, Schan C, Dalton CB, Salley AN. The relationship between stress and symptoms of gastroesophageal reflux: the influence of psychological factors. Am J Gastroenterol 1993; 88: 11-9.
26. Ford AC, Talley NJ, Schoenfeld PS, Quigley EMM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
27. Wu CY, Chou LT, Chen HP, Chang CS, Wong PG, Chen GH. Effect of fluoxetine on symptoms and gastric dysrhythmia in patients with functional dyspepsia. Hepatogastroenterology 2003; 50: 278-83.
28. Van Kerkhoven LAS, Laheij RJF, Aparicio N, De Boer WA, Van Den Hazel S, Tan AC, Witteman BJ, Jansen JB et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008; 6: 746-52.
29. Braak B, Klooker T, Wouters M, Lei A, van den Wijngaard R, Boeckxstaens G. Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011; 34: 638-48.
30. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000; 157: 1423-8.
31. Shi G, Des Varannes SB, Scarpignato C, Le Rhun M, Galmiche J. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995; 37: 457-64.